TOPSTOCKS.COM

    STOCK ANALYSIS

    *Sponsored
    Wednesday, July 15, 2026

    *Sponsored

    Low Float Biopharma Profile (Nasdaq: CVKD) Hits Monday's Radar Behind 5 Potential Catalysts

    July 15, 2026

    Greetings Readers,

    A dynamic force in the cardiovascular treatment space has recently made a strategic acquisition that’s turning heads across the biopharma community.

    This move strengthens its position in addressing some of the most pressing unmet needs in heart health, expanding both research depth and therapeutic reach.

    With a focus on advancing late-stage clinical programs and accelerating timelines, the company is clearly stepping into a new phase of momentum.

    For those watching the intersection of innovation and patient care, this latest development signals something significant worth a closer look, and a deeper appreciation for what’s quietly taking shape in the field of cardiovascular medicine.

    Now, mix in a low float of fewer than 2Mn shares and a pair of analyst targets suggesting SIGNIFICANT upside potential, and there's no doubt why this Nasdaq profile just rocketed up my watchlist.

    Drop what you're doing and consider this under-the-radar idea for your radar:

    *Cadrenal Therapeutics, Inc. (Nasdaq: CVKD)*

    Cadrenal Therapeutics, Inc. is a biopharmaceutical company developing therapeutics for patients with cardiovascular disease.

    Cadrenal’s lead investigational product is tecarfarin, a novel oral vitamin K antagonist anticoagulant that addresses unmet needs in anticoagulation therapy.

    Tecarfarin is a reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation.

    And based on several potential breakout catalysts, (Nasdaq: CVKD) has found its way to the top of my watchlist. Check them out:

    1. A Low Float Could Create An Environment Of Heightened Volatility Potential.
    2. A $45 Analyst Target Suggests Triple-Digit Potential Upside From Current Levels.
    3. Another Analyst Reiterates A $30 Target For CVKD.
    4. A Major Acquisition Has Game-Changing Potential For Cadrenal's Pipeline.
    5. The Company Announced Clinical Trial Initiation Plans ("Important Step Forward.")

    But more on those in a second...

    Company Breakdown: Cadrenal Therapeutics, Inc. (Nasdaq: CVKD)

    Cadrenal Therapeutics is a late-stage biopharmaceutical company developing tecarfarin, an investigational anticoagulant designed as a superior and safer Vitamin K antagonist (VKA) for patients with implanted cardiac devices or rare cardiovascular conditions.

    The company strives to improve patient outcomes and reduce major adverse events among these populations, who currently lack any approved chronic anticoagulation options besides warfarin, a medication known for its serious side effects and complex management requirements.

    Through its innovative approach, Cadrenal aims to alleviate some of the most significant challenges faced by patients and healthcare providers who rely on warfarin.

    Cadrenal’s Phase 3-ready drug candidate, tecarfarin, represents a novel VKA anticoagulant supported by extensive data suggesting its potential to be superior to warfarin, with the possibility of fewer adverse events such as strokes, heart attacks, bleeding, and death.

    Tecarfarin has received orphan drug designation for heart failure patients with left ventricular assist devices (LVADs), as well as both orphan drug and fast track status for end-stage kidney disease (ESKD) patients with atrial fibrillation (Afib).

    The company is actively pursuing pivotal clinical trials and exploring clinical and commercial partnership opp's.

    Cadrenal also plans to investigate tecarfarin in patients with mechanical heart valves who experience anticoagulation difficulties due to genetic warfarin resistance, polypharmacy, or kidney impairment.

    Tecarfarin is metabolized through a different pathway than warfarin, and data indicate that its efficacy remains unaffected by common drug-drug interactions or kidney impairment, challenges that are prevalent among these patient populations.

    Phase 2/3 clinical trials have demonstrated that tecarfarin may offer greater stability and increased time in therapeutic range, which is inversely correlated with major adverse events.

    As the only new VKA blood thinner in development specifically for warfarin-dependent patients with implanted cardiac devices or rare cardiovascular conditions, Cadrenal is boldly challenging the status quo, seeking to innovate a new anticoagulant that delivers better care to underserved patients.

    Tecarfarin’s Metabolic Advantage

    img

    Tecarfarin Clinical Development Pipeline

    img

    Grab Sources Here: CVKD Website.

    Factor XI plays only a minor role in normal clotting but is a major driver of pathological thrombosis. By selectively targeting FXIa, Frunexian and EP-7327 could deliver potent antithrombotic effects without dramatically increasing bleeding risk.

    This is why Factor XIa inhibitors have become one of the hottest areas of cardiovascular drug development. Big pharma has committed billions of dollars to acquire or license programs in this space, validating the opportunity Cadrenal now controls.

    And as I mentioned earlier, (Nasdaq: CVKD) has several potential catalysts to consider immediately. Check them out:

    #1. CVKD Potential Catalyst, A Low Float Could Create An Environment Of Heightened Volatility Potential.

    According to info from the Yahoo Finance website, CKVD has a very low float..

    The website reports this profile to have roughly 1.50Mn shares in its float.

    Why is that important? It's important on one crucial level. Volatility potential.

    If positive company news appears towards the end of 2025, could it provide a breakout spark when paired with this volatile potential?

    #2. CVKD Potential Catalyst, A $45 Analyst Target Suggests Triple-Digit Potential Upside From Current Levels.

    Last month, Noble Capital Markets analyst, Robert LeBoyer, reiterated his $45 price target.

    From Friday's 4:00PM EST closing valuation, that target provides CVKD with a potential upside of 225+%!

    Details from the report:

    Conclusion. The product acquisition builds the pipeline and adds products with a different mechanism of action for complementary indications. A clinical study testing tecarfarin in patients during the high-risk period after starting renal dialysis is planned for later this year, with a study in mechanical ventricular assist devices planned for FY2026. We reiterate our Outperform rating and $45 price target.

    #3. CVKD Potential Catalyst, Another Analyst Reiterates A $30 Target For CVKD.

    Another analyst, David Bautz of Zacks Small-Cap Research, reiterated their $30 target for CVKD this summer.

    From its 4:00PM EST close on Friday, that targets suggests 120+% potential upside for CVKD.

    Report highlights:

    We look forward to additional updates from the company regarding the upcoming Phase 3 trial of tecarfarin in LVAD patients. Having Abbott as a partner for the Phase 3 trial is a tremendous opp. for the company as Abbott has extensive experience working with LVAD patients and conducting successful trials with that population. With no changes to our model our valuation remains at $30 per share.

    #4. CVKD Potential Catalyst, A Major Acquisition Has Game-Changing Potential For Cadrenal's Pipeline.

    Cadrenal Therapeutics Enhances Anticoagulation Pipeline Through Acquisition of eXIthera’s Portfolio of Factor XIa Inhibitors

    Acquisition significantly enhances the Company’s pipeline by adding novel assets in acute and chronic anticoagulation settings

    Company is strategically poised to deliver differentiated therapeutics across the spectrum of cardiovascular thrombotic risk

    PONTE VEDRA, Fla., Sept. 15, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics to overcome the gaps in anticoagulation therapy, today announced the acquisition of the assets of eXIthera Pharmaceuticals (“eXIthera”), including its proprietary portfolio of investigational intravenous (IV) and oral Factor XIa inhibitors. The acquisition significantly enhances Cadrenal’s pipeline, adding drug candidates that address large and underserved segments of the current $38Bn global anticoagulation market.

    eXIthera’s lead asset, frunexian, is a first-in-class, Phase 2-ready intravenous (IV) Factor XIa inhibitor designed for acute care settings where contact activation of coagulation by medical devices plays a significant role, such as cardiopulmonary bypass, catheter thrombosis, and other blood-contacting implanted cardiac devices. The acquisition also includes EP-7327, an oral Factor XIa inhibitor, for the prevention and treatment of major thrombotic conditions.

    “With this acquisition, Cadrenal is the only company in the world developing a novel vitamin K antagonist (tecarfarin) and Factor XIa inhibitors, a promising new class of anticoagulants,” said Quang X. Pham, Chairman and CEO of Cadrenal Therapeutics. “These newly acquired assets will expand Cadrenal’s capabilities in an effort to address even more critical gaps in current antithrombotic treatment, especially for patients for whom current therapies are unreliable or carry excessive bleeding risk.”

    “This acquisition reinforces Cadrenal’s long-term vision of becoming a category leader in anticoagulation,” added Pham. “With tecarfarin planning a trial in patients with end-stage kidney disease transitioning to dialysis, our plans for LVAD patients, and the current addition of frunexian and EP-7327, we believe that Cadrenal is strategically positioned to deliver differentiated therapeutics across the entire spectrum of patients with cardiovascular thrombotic risk.”

    Read the full article here.

    #5. CVKD Potential Catalyst, The Company Announced Clinical Trial Initiation Plans ("Important Step Forward.")

    Cadrenal Therapeutics Announces Clinical Trial Initiation Plans for Tecarfarin in Patients with End-Stage Kidney Disease (ESKD) Transitioning to Dialysis

    Advances knowledge about the use of tecarfarin in patients with severe kidney impairment, including dialysis

    Pivotal step forward in pursuit of ESKD + Atrial Fibrillation (AFib) registration trial Addresses a critical current treatment gap in patients with ESKD

    PONTE VEDRA, Fla., August 05, 2025, (BUSINESS WIRE), Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company focused on developing transformative therapeutics that specifically address limitations of current anticoagulation therapy, today announced clinical trial initiation plans for its lead late-stage drug candidate, tecarfarin, in patients with ESKD who are transitioning to dialysis. Enrollment is planned to begin later this year and will include patients with and without atrial fibrillation (AFib).

    Patients with severe kidney disease are already at high risk for thrombotic cardiovascular events such as myocardial infarction and stroke, along with a much greater risk of AFib and venous thromboembolism compared to subjects with normal kidney function. When ESKD patients require dialysis, their transition period comes with even greater risk of myocardial infarction, stroke, and a substantial increase in mortality.

    "There is a critical need for safe, effective anticoagulants for use in ESKD patients," said Quang X. Pham, Chairman and CEO of Cadrenal Therapeutics. "Tecarfarin’s orphan drug and fast-track designations in ESKD patients with AFib underscore this need, and we are excited to advance this program. This study will be an important step forward for the continued development of tecarfarin in ESKD and in other areas with real opp's to improve patient outcomes with a potentially better vitamin K antagonist."

    Read the full article here.

    (Nasdaq: CVKD) Recap, 5 Potential Breakout Catalysts Lead The Way

    • A Low Float Could Create An Environment Of Heightened Volatility Potential.
    • A $45 Analyst Target Suggests Triple-Digit Potential Upside From Current Levels.
    • Another Analyst Reiterates A $30 Target For CVKD.
    • A Major Acquisition Has Game-Changing Potential For Cadrenal's Pipeline.
    • The Company Announced Clinical Trial Initiation Plans ("Important Step Forward.")

    Now initiated: coverage is officially a "go" on Cadrenal Therapeutics, Inc. (Nasdaq: CVKD).

    When updates are available, I'll get them out to you quickly. Talk soon.

    Sincerely,

    TopStocks

    Cadrenal Therapeutics, Inc.

    NASDAQ: CVKD

    $12.68
    -0.24 (-1.86%)
    Market Cap

    25.95M

    EPS

    -8.88

    Next Earnings

    February 26, 2026

    Last updated: 7/15/2026, 8:59:03 PM

    Stock Alerts

    Get instant notifications for CVKD price movements and news.

    Unsubscribe anytime. SMS rates may apply.

    Get Stock Alerts

    Never miss important market movements. Get real-time alerts via SMS and email.

    By subscribing, you agree to receive stock alerts. You can unsubscribe at any time. Message and data rates may apply for SMS alerts.

    MASTER LEGAL DISCLAIMER

    Last Updated: Apr 30, 2026

    Publisher: Relqo Media LLC (Wyoming, United States)

    Subject Company: Cadrenal Therapeutics, Inc. (CVKD)

    IMPORTANT SUMMARY — PLEASE READ FIRST

    This website and any affiliated digital materials are published by Relqo Media LLC, a Wyoming marketing agency that has been compensated in cash by Penzance LLC to produce and distribute promotional content regarding Cadrenal Therapeutics, Inc. (NASDAQ: CVKD). This communication is a paid advertisement, not a research report, not investment advice, and not an independent publication. Relqo Media is not a broker-dealer, investment adviser, or securities analyst. Investing in small-cap or microcap securities is extremely speculative and may result in the total loss of your investment. We strongly urge all viewers to consult a licensed investment professional and perform their own due diligence.

    1. NATURE AND INTENT OF THIS COMMUNICATION

    Relqo Media LLC is a for-profit marketing agency engaged in paid promotions of public companies. The content we produce is strictly commercial and intended to create temporary public awareness, visibility, and short-term market activity around the featured company. This material is not impartial. All readers should interpret our content as a paid commercial advertisement and not as an editorial, research article, or independent commentary. We create advertisements, not analysis. These Communications are not intended to be factual evaluations of the company’s operations or investment merit.

    2. COMPENSATION FOR CADRENAL THERAPEUTICS, INC. (CVKD)

    Relqo Media LLC ("Relqo Media") has been engaged by Penzance LLC to provide promotional media and digital investor awareness services with respect to Cadrenal Therapeutics, Inc. (NASDAQ: CVKD). The following details outline the nature, scope, and financial terms of this engagement:

    • Relqo Media received cash compensation of $25,000 for a 5 day campaign covering April 27th , 2026, through May 1st 2026.
    • Relqo Media received cash compensation of $25,000 for a 5 day campaign covering March 9th , 2026, through March 13th 2026.
    • Relqo Media received cash compensation of $25,000 for a 4 day campaign covering March 1st , 2026, through March 5th 2026.
    • Relqo Media received cash compensation of $25,000 for a 5 day campaign covering February 23rd , 2026, through february 28th 2026.
    • Relqo Media received cash compensation of $25,000 for a 5 day campaign covering February 18th , 2026, through february 23rd 2026.
    • Relqo Media received cash compensation of $25,000 for a 6 day campaign covering January 25th , 2026, through January 30th 2026.
    • Relqo Media received cash compensation of $25,000 for a 7 day campaign covering January 12, 2026, through January 19, 2026.
    • Relqo Media received cash compensation of $25,000 for a campaign covering December 10, 2025, through December 17, 2025.
    • Relqo Media received cash compensation of $25,000 for a campaign covering December 2, 2025, through December 10, 2025.
    • Relqo Media continued to receive cash compensation on a week to week basis at a rate of $25,000 per week, paid weekly, from July 26, 2025, through September 9, 2025, resulting in aggregate additional compensation of $150,000.
    • Relqo Media received additional cash compensation at the same weekly rate of $25,000 per week, paid weekly, covering the period from June 26, 2025, through July 26, 2025, resulting in aggregate compensation of $100,000.
    • Relqo Media received cash compensation from Penzance LLC for digital investor awareness and promotional services at a rate of $25,000 per week, paid weekly, beginning January 1, 2025, through July 1, 2025, resulting in aggregate compensation of $650,000 during that period.
    • Total Compensation: As of January 19, 2026, Relqo Media has received cumulative cash compensation of $975,000 from Penzance LLC for services rendered in connection with CVKD.
    • Future Compensation: This engagement continues on an open ended basis at a rate of $25,000 per week, paid weekly, until terminated by either party. Accordingly, Relqo Media will continue to receive compensation at this rate beyond January 19, 2026, unless and until such agreement is terminated or modified in writing.
    • Nature of Services: Relqo Media's services include, but are not limited to, creating, publishing, and distributing digital media, promotional articles, newsletters, websites, investor awareness content, social media campaigns, email/SMS marketing, and other investor-focused communications designed to raise awareness of CVKD among retail and institutional investors.
    • Conflict of Interest Statement: Because Relqo Media has been, and will continue to be, compensated directly by Penzance LLC for its services, this relationship represents a material conflict of interest. Relqo Media's communications regarding CVKD, including but not limited to newsletters, articles, press releases, advertisements, websites, emails, SMS alerts, and social media posts, should be understood as paid advertisements that are inherently biased.
    • Securities Ownership Disclosure: Penzance LLC and/or its affiliates, officers, directors, or associated individuals may own, acquire, or dispose of securities of Cadrenal Therapeutics, Inc. before, during, or after the campaign period. This means that while Relqo Media is being compensated to promote CVKD, the entities paying for such services may simultaneously engage in securities transactions involving CVKD stock, which could result in gains or losses to those parties independent of Relqo Media's activities.
    • Investor Warning: All readers, investors, and market participants should assume that any and all promotional communications disseminated by Relqo Media regarding CVKD are issued for the purpose of increasing investor awareness and may have the effect of increasing trading volume and/or the market price of CVKD's securities. Investors are strongly cautioned to conduct their own independent research, due diligence, and analysis of CVKD, including review of all filings made with the Securities and Exchange Commission (SEC), prior to making any investment decision.

    This relationship creates a material conflict of interest. All content distributed by Relqo Media LLC regarding CVKD should be viewed as promotional, financially motivated, and inherently biased.

    3. INTENDED AUDIENCE

    These Communications are directed solely to U.S.-based, self-directed investors who understand the risks of investing in microcap and Nasdaq-listed securities. The content is not intended for children, seniors, retirement accounts, or individuals with limited experience in securities trading. These Communications are not intended to guide investment for long-term portfolio management or financial planning purposes.

    4. NO ENDORSEMENT OR VERIFICATION OF COMPANY CLAIMS

    Relqo Media LLC does not, and has not, independently verified, investigated, audited, or substantiated any statements, representations, or claims made by the featured company, its officers, directors, employees, affiliates, agents, press releases, marketing materials, or any third-party sources.

    Any and all information regarding Cadrenal Therapeutics, Inc. (NASDAQ: CVKD)—including but not limited to business descriptions, operational updates, clinical trial progress, scientific data, partnerships, revenue projections, market opportunity estimates, or strategic plans—should be assumed to be unverified, unaudited, incomplete, potentially inaccurate, and subject to change without notice.

    We make no warranties or representations as to the truthfulness, accuracy, reliability, or completeness of such information, and you should not interpret our publication of these statements as an endorsement or confirmation of their validity.

    You should not rely on any company-provided claims, projections, or forward-looking statements for the purpose of making an investment decision. All such statements may be speculative, overstated, selectively presented, or based on assumptions that may never materialize.

    If you choose to invest, you do so entirely at your own risk, and you should conduct thorough, independent due diligence—including reviewing SEC filings, consulting licensed investment professionals, and obtaining independent verification of any material facts—before making any investment decision.

    5. MARKET INFLUENCE AND TRADING PATTERN EXPECTATION

    Historically, promotional campaigns for microcap and small-cap securities—particularly those driven by paid advertising—often cause temporary, artificial, and unsustainable increases in share price and trading volume. These movements are typically fueled by short-term speculative interest, promotional circulation, algorithmic trading activity, and momentum-based retail buying rather than any change in the underlying business, operations, or financial condition of the company.

    You should assume and expect that:

    • CVKD’s share price may experience sharp, rapid, and potentially extreme increases during the period of active promotion;
    • Trading volume may spike dramatically due to speculative buying pressure, news catalysts amplified by promotional activity, and social media or online forum chatter;
    • Once buying interest subsides, selling begins, or the promotion ends—which may occur suddenly and without notice—the share price may decline precipitously, potentially returning to pre-promotion levels or lower, often within days or even hours; and
    • These price and volume movements are not reflective of intrinsic value and may have no correlation to the company’s actual fundamentals or long-term business prospects.

    Past market behavior shows that such promotional price spikes are frequently followed by steep losses, which can be rapid and irreversible. If you purchase shares during or shortly after a promotional period, you should be prepared for the high probability of losing a substantial portion, or all, of your investment.

    By engaging with our content, you acknowledge and agree that you fully understand the speculative, volatile, and high-risk nature of securities subject to promotional activity, and you will not hold Relqo Media LLC responsible for any losses resulting from such trading patterns.

    6. NO RELIANCE – INVESTOR RESPONSIBILITY

    The burden of research, verification, and risk assessment rests entirely with you, the reader. All content produced and distributed by Relqo Media LLC is promotional in nature and should not be the basis for any investment decision. We are not responsible for your interpretation or use of the information contained herein.

    You are solely responsible for:

    • Reviewing and analyzing all publicly available information, including but not limited to SEC filings, audited financial statements, and official company disclosures;
    • Consulting with a licensed, qualified investment professional, attorney, or tax adviser before making any investment decision;
    • Understanding and accepting the risks inherent in microcap and early-stage public companies, which may include extreme volatility, illiquidity, lack of financial transparency, insider selling, share dilution, regulatory challenges, and business failure.

    We make no warranties or representations as to the accuracy, completeness, timeliness, or reliability of any information presented. Any data, figures, or statements regarding the featured company’s business, market opportunity, future performance, or partnerships may be incomplete, outdated, or incorrect. You should assume that certain information is based on third-party sources we have not independently verified.

    By viewing our materials, you agree that:

    • You will not rely solely on our communications in making an investment decision;
    • You accept full responsibility for conducting independent due diligence; and
    • Relqo Media LLC and its affiliates will not be liable for any losses or damages arising from your reliance on our content.

    7. FORWARD-LOOKING STATEMENTS, ASSUMPTIONS, AND ACCURACY NOTICE

    Our materials may include “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as well as other predictive or aspirational language regarding future events, performance, or results. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “may,” “will,” “should,” “could,” “projects,” “estimates,” “potential,” and similar expressions are intended to identify such statements. These statements are inherently uncertain, based on current expectations, estimates, and assumptions that may prove to be incorrect, incomplete, or no longer applicable at the time you read them.

    Forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied. Such factors include, but are not limited to: changes in market conditions, regulatory decisions, the outcome of clinical trials, competitive pressures, the availability of financing, and broader economic or geopolitical developments.

    Additionally, some information presented in our content is derived from third-party sources, company press releases, or statements from officers, directors, or affiliates of the featured company. We do not independently verify or guarantee the accuracy, completeness, or timeliness of such information. Any claim, projection, or forward-looking statement should be considered purely speculative and potentially outdated..

    You should not place undue reliance on forward-looking statements or assume that they will prove to be accurate. Relqo Media LLC undertakes no obligation to update or revise any forward-looking statements to reflect subsequent events, changes in circumstances, or the emergence of new information, except as required by law.

    8. INFORMATION SOURCING, BIAS, AND ACCURACY

    We use publicly available information including company websites, press releases, and promotional materials supplied by paying clients or related parties. We do not verify or validate this data.

    Assume all information presented by Relqo Media is:

    • Subjective,
    • Not independently verified,
    • Created to highlight potential upside and omit downsides,
    • Not suitable as the basis for any investment decision.

    9. OWNERSHIP AND TRADING CONFLICTS

    Relqo Media LLC, its contractors, members, and affiliates may hold or acquire shares in the companies we promote, including CVKD. We may buy or sell such shares without prior notice. These transactions may occur before, during, or after a promotional campaign and may affect market pricing. We are not obligated to update readers on our trading activity or affiliate holdings.

    10. MARKETING TOOLS, DATA COLLECTION, AND USER CONSENT

    We use a range of outreach and promotional tools, including:

    • Email and newsletter distributions,
    • SMS/MMS text campaigns,
    • Social media posts and influencers,
    • Google and native display ads,
    • Press releases, video marketing, and paid content distribution.

    By engaging with our content, you consent to receive ongoing marketing communications. You may unsubscribe, but your data may be retained for audit or compliance purposes. Please refer to our Privacy Policy for further details.

    11. ADVERTISING LAW COMPLIANCE

    Relqo Media LLC produces promotional content in accordance with the advertising disclosure standards set forth by the Federal Trade Commission (FTC) and the SEC’s interpretations of sponsored investment-related communications.

    We make good-faith efforts to disclose all:

    • Compensation arrangements,
    • Conflicts of interest,
    • Risks,
    • Limitations of our role, and
    • The promotional nature of this content.

    We do not provide investment recommendations under any regulatory framework including, but not limited to, SEC Regulation Analyst Certification, FINRA Rule 2210, or Regulation Best Interest.

    12. NON-U.S. USERS

    This material is intended solely for distribution within the United States. If you are accessing this site from outside the U.S., you are responsible for complying with your country’s laws. Relqo Media disclaims liability for access from non-U.S. jurisdictions where investor promotion, marketing, or solicitation of securities is restricted or prohibited.

    13. DISCLAIMER OF WARRANTIES AND LIMITATION OF LIABILITY

    All content is provided “as-is” and without warranties of any kind, either express or implied. Relqo Media LLC disclaims any and all liability for:

    • Investment losses,
    • Inaccuracies,
    • Technical delays,
    • User misunderstandings,
    • Omissions or errors in content.

    Total liability for any claim shall not exceed one hundred dollars ($100).

    14. LEGAL GOVERNANCE AND DISPUTE RESOLUTION

    All matters arising out of this disclaimer shall be governed by the laws of the State of Wyoming. You agree that any dispute shall be resolved exclusively through binding arbitration under the rules of the American Arbitration Association, to be held in Sheridan County, Wyoming. Class action claims and group arbitration are expressly prohibited.

    15. NON-SOLICITATION AND GEOGRAPHIC LIMITATIONS

    Nothing in our content constitutes a general solicitation or a personal securities recommendation. If you reside in a jurisdiction where such communications are unlawful, you must exit this site and discontinue engagement with our content.

    16. FINAL NOTICE – ACCEPTANCE OF TERMS

    We reserve the right to update this Disclaimer at any time without notice. Your continued use of our services or content constitutes acceptance of the most recent version.

    If you do not accept all terms of this disclaimer in full, you must:

    • Exit our websites,
    • Unsubscribe from our communications,
    • Discontinue viewing all Relqo Media promotional content.

    17. NO RELIANCE

    By viewing or engaging with this content, you agree that:

    • You will not rely on any statements made by Relqo Media for investment purposes,
    • You waive any claim that our content was a material factor in your investment decision,
    • You have read, understood, and accepted this disclaimer in full.

    © 2024 Relqo Media LLC. All Rights Reserved.

    Legal Contact: 📧 support@topstocks.com

    Mailing Address: 1309 Coffeen Ave Ste 1200, Sheridan, WY 82801

    Affiliate Disclosure: Relqo Media LLC owns and operates TopStocks.com and all affiliated digital properties.